RECOVERY trial will evaluate REGN-COV2 investigational antibody cocktail in the UK
14 Sep 2020
The University of Oxford and its partner Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that RECOVERY (Randomised Evaluation of COVid-19 thERapY), one of the world’s largest randomised clinical trials of potential COVID-19 treatments, will evaluate Regeneron’s investigational anti-viral antibody cocktail, REGN-COV2.
The Phase 3 open-label trial in patients hospitalised with COVID-19 will compare the effects of adding REGN-COV2 to the usual standard-of-care versus standard-of-care on its own.
Professor Fiona Watt, Executive Chair of the Medical Research Council, part of UKRI, said: “With our support, the RECOVERY trial has previously found the most clinically effective treatment for COVID-19 so far, dexamethasone.
"The same UK-wide trial will now test a new treatment designed specifically to combat the virus that causes the disease. Monoclonal, or targeted, antibodies are already used to treat cancer and autoimmune diseases. The new trial will tell us whether antibodies that attack the virus can be an effective treatment for Covid-19.”
Read the full story on the UKRI website.